Top Story

Value of PFS as surrogate in NSCLC varies considerably

March 31, 2015

The value of providing access to new treatments for non–small cell lung cancer based on improvements in PFS varied according to incremental treatment cost, the value of life and the correlation between PFS and OS, according to results of a modeling study.

“Since 1992, the U.S. FDA has provided accelerated approval of promising treatments for serious conditions on the basis of ‘surrogate’ endpoints to expedite patient access to potentially effective innovations,” Darius N. Lakdawalla, PhD, of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California, and colleagues wrote. “While granting earlier access to new treatments, this strategy also risks introducing treatments that later proved ineffective.”

Michael Boeckh In the Journals

Antivirals improve CMV pneumonia outcomes after HCT

March 30, 2015
Outcomes of cytomegalovirus pneumonia after hematopoietic cell transplantation have improved modestly over the past 25 years largely due to antiviral treatment and…
FDA News

FDA grants priority review for expanded use of Kyprolis in relapsed multiple myeloma

March 30, 2015
The FDA today accepted the supplemental new drug application of carfilzomib for the treatment of patients with relapsed multiple myeloma who have received at least one…
Dennis Slamon Industry News

Panel of cancer experts highlight advancements in precision medicine

March 30, 2015
Advancements in the understanding of cancer genetics have led to important breakthroughs in precision medicine, according to a Columbia University media briefing on the…

Experts discuss whether shift in Medicare will reduce costs, improve quality of care

March 30, 2015
In response to concerns over Medicare’s current fee-for-service payment system, the Obama administration announced in January that by 2018 Medicare instead will…
More News Headlines »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
thumbnail for video 4126759064001

Solid organ transplant recipients at higher risk for skin cancer

March 22, 2015
SAN FRANCISCO – In this video, Sarah Tuttleton Arron, MD, PhD, FAAD, discusses her research on mortality from…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan